Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Argentina Joins International Pharmaceutical Regulators Programme

Executive Summary

Argentina’s drug regulator has become the newest member of the International Pharmaceutical Regulators Programme.

You may also be interested in...

Iran Joins Global Drug Regulators Group

Members of the International Pharmaceutical Regulators Programme have met in Amsterdam, where they discussed new topics including potential opportunities for reliance and use of real-world data in pharmacovigilance. Iran has joined the group.

US FDA Pressing Industry To Use Standards For Cell and Gene Therapies

A US FDA official is exhorting the biopharmaceutical industry to adopt standards to help in developing new cell and gene therapy products, yet this may pose difficulties as there is a lack of standards in this space, particularly in areas such as cell viability, chain of identity and viral vector gene quantification.

Global Regulators Promote Convergence With New Biowaiver Evaluation Template

An international group of pharmaceutical regulators has issued a new template that can be used to assess biowaiver applications for additional drug strengths.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts